In addition, long-term (8–17 weeks) supplementation of AMF suppresses hepatic steatosis with decreasing lipogenesis-related gene expression, including Cebpa, Fabp4, and Slc27a4 in HFD-fed mice [19,26,27]. The gene discussed is FABP4; the disease is Hepatic steatosis.